The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial
Open accessAbstract
Background— Abciximab reduces major adverse cardiac events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Intracoronary abciximab bolus application results in high local drug concentrations and may be more effective than a standard intravenous bolus. Methods and Results— Patients undergoing primary PCI were randomized to either intracoronary (n=77) or intravenous (n=77) bolus abciximab administration with subsequent 12-hour intravenous infusion. The primary end point was infarct size and extent of microvascular obstruction as assessed by delayed enhancement magnetic resonance. Secondary end points were ST-segment resolution at 90 minutes, Thrombolysis in Myocardial Infarction flow and perfusion grades after PCI, and the occurrence of major adverse cardiac events within 30 days. The median infarct size was 15.1% (interquartile range, 6.1% to 25.2%) in the intracoronary versus 23.4% (interquartile range, 13.6% to 33.2%) in the intravenous group ( P =0.01). Similarly, the extent of microvascular obstruction was significantly smaller in intracoronary compared with intravenous abciximab patients ( P =0.01). Myocardial perfusion measured as early ST-segment resolution was significantly improved in intracoronary patients with an absolute ST-segment resolution of 77.8% (interquartile range, 66.7% to 100.0%) versus 70.0% (interquartile range, 45.2% to 83.5%; P =0.006). The Thrombolysis in Myocardial Infarction flow after PCI was not different between treatment groups ( P =0.51), but there was a trend toward an improved perfusion grade ( P =0.09). There also was a trend toward a lower major adverse cardiac event rate after intracoronary versus intravenous abciximab application (5.2% versus 15.6%; P =0.06; relative risk, 0.33; 95% CI, 0.09 to 1.05). Conclusions— Intracoronary bolus administration of abciximab in primary PCI is superior to standard intravenous treatment with respect to infarct size, extent of microvascular obstruction, and perfusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Kim, R. J., Wu, E., Rafael, A., Chen, E.-L., Parker, M. A., Simonetti, O., Klocke, F. J., Bonow, R. O., & Judd, R. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432003 · Cited by 3,306
The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I Findings
The TIMI Study Group* (1985) · New England Journal of Medicine · doi:10.1056/nejm198504043121437 · Cited by 3,188
Wu, K. C., Zerhouni, E. A., Judd, R. M., Lugo-Olivieri, C. H., Barouch, L. A., Schulman, S. P., Blumenthal, R. S., & Lima, J. A. C. (1998) · Circulation · doi:10.1161/01.cir.97.8.765 · Cited by 1,357
Wagner, A., Mahrholdt, H., Holly, T. A., Elliott, M. D., Regenfus, M., Parker, M., Klocke, F. J., Bonow, R. O., Kim, R. J., & Judd, R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12389-6 · Cited by 1,307
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone, G. W., Grines, C. L., Cox, D. A., Garcia, E., Tcheng, J. E., Griffin, J. J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013404 · Cited by 1,277
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J.-M., Morice, M.-C., Maillard, L., Pansiéri, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442503 · Cited by 1,186
Gibson, C. M., Cannon, C. P., Murphy, S. A., Ryan, K. A., Mesley, R., Marble, S. J., McCabe, C. H., Van de Werf, F., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.2.125 · Cited by 858
Brener, S. J., Barr, L. A., Burchenal, J. E. B., Katz, S., George, B. S., Jones, A. A., Cohen, E. D., Gainey, P. C., White, H. J., Cheek, H. B., et al. (1998) · Circulation · doi:10.1161/01.cir.98.8.734 · Cited by 722
Facilitated PCI in Patients with ST-Elevation Myocardial Infarction
Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Janssens, L., Andersen, H. R., Betriu, A., Savonitto, S., Adamus, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706816 · Cited by 696
Cited by
Myocardial No-Reflow in Humans
Niccoli, G., Burzotta, F., Galiuto, L., & Crea, F. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.054 · Cited by 853
Stone, G. W. (2012) · JAMA · doi:10.1001/jama.2012.421 · Cited by 541
Patel, M. R., Smalling, R. W., Thiele, H., Barnhart, H. X., Zhou, Y., Chandra, P., Chew, D., Cohen, M., French, J., Perera, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1280 · Cited by 414
Self-citationCardiovascular Magnetic Resonance in Patients With Myocardial Infarction
Kim, H. W., Farzaneh-Far, A., & Kim, R. J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.059 · Cited by 338
Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134
Metadata
- Authors
- Thiele, H., Schindler, K., Friedenberger, J., Eitel, I., Fürnau, G., Grebe, E., Erbs, S., Linke, A., Möbius-Winkler, S., Kivelitz, D., & Schuler, G.
- Venue
- Circulation
- Published
- 2008-07
- Volume
- 118
- Issue
- 1
- Pages
- 49-57
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1983567586
- Cited by
- 303
- References
- 27
- FWCI
- 24.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial. https://app.cochat.ai/papers/10.1161/circulationaha.107.747642
- The paper
- Thiele, H., Schindler, K., Friedenberger, J., Eitel, I., Fürnau, G., Grebe, E., Erbs, S., Linke, A., Möbius-Winkler, S., Kivelitz, D., & Schuler, G. (2008). Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial. Circulation. https://doi.org/10.1161/circulationaha.107.747642
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.